Matty Britland

[Matty Britland @mbritland]

@FordePatrick @perth_meso_dr @TOGAANZ @PrECOGonc @MartinStockler @RamalingamMD @eaonc Such an incredibly important study

[Omico Australia @OmicoAustralia]

Last day of #TOGAASM2023 🤝 @mbritland is representing Team Omico in Melbourne – be sure to say hello if you see him there. Thanks @TOGAANZ  for bringing together such an exceptional group of speakers and delegates for crucial discussions on #lungcancer and #mesothelioma

[Matty Britland @mbritland]

@OmicoAustralia @MilitaZaheed @Subo81495328 @fpylin @DrDamienKee Great work all

[Omico Australia @OmicoAustralia]

We are really excited to have Matty and PharmedSciences PTY onboard as we start to implement our PrOSPeCT program. Together with #cancermeetsitsmatch

[Matty Britland @mbritland]

@OmicoAustralia Truly privileged to be part of this.

[Matty Britland @mbritland]

https://t.co/NX0t94tNGX

[Omico Australia @OmicoAustralia]

With thanks to @RareCancers Omico’s @ProfDMThomas and @bgoodwi6 were at @PressClubAust today. We wait in anticipation…

[Matty Britland @mbritland]

@PrECOGonc @RutgersCancer Small typo. This is a Phase III study.

[Anna Nowak @perth_meso_dr]

I am delighted to share that the #DREAM3R clinical trial in #mesothelioma opened in #NewZealand today. Thanks to #NZ oncologists and patients for your support of this important #clinicaltrial
@TrialsCentre @TOGAANZ @MartinStockler @NCARD_research @UWAresearch

[PrECOG @PrECOGonc]

The #PrE0506/DREAM3R #clinicaltrial is now enrolling patients with malignant pleural #mesothelioma at @WinshipAtEmory, @UMRogelCancer, @KimmelCancerCtr, @PennCancer, @ClevelandClinic, & Metro Minnesota Community Oncology Research Consortium. Learn more: https://t.co/BTJ59y6qub

[Elsa Anagnostou @ValsamoA]

The DREAM3R/PrE0506 trial builds on the promising efficacy of chemo+durva in the DREAM (PI @perth_meso_dr) and Pre0505 (PI @FordePatrick) trials and will provide a unique opportunity to understand the #genomic wiring of response.
@PrECOGonc @TOGAANZ @hopkinskimmel #curemeso

[Thoracic Oncology Group of Australasia @TOGAANZ]

Hear Prof Anna Nowak @perth_meso_dr and active @TOGAANZ member on this podcast. Prof Nowak leads the Ph3 #DREAM3R 1L mesothelioma #clinicaltrial examining chemo+/- IO in a collaboration w @TOGAANZ @PrECOGonc @TrialsCentre @FordePatrick #LCSM

[Mesothelioma Applied Research Foundation @curemeso]

NEW: A phase 3 randomized clinical trial looking into the efficacy of combination chemotherapy with #Immunotherapy in #mesothelioma is now open in the United States and Australia. https://t.co/Qt1tufs65c

[PrECOG @PrECOGonc]

Phase II #clinicaltrial PrE0505 showed encouraging results when investigators added durvalumab to standard chemo for patients w/ malignant pleural #mesothelioma. Phase III study PrE0506/DREAM3R aims to confirm these findings. Learn more: https://t.co/G2ZXiFEbVD #LCSM

[Patrick Forde @FordePatrick]

Huge effort by all to get this trial up & running in particular @perth_meso_dr @MartinStockler @RamalingamMD ! We believe this trial will be a good option for our pts with newly dx unresectable meso, particularly for epithelioid histology. Now open @HopkinsThoracic ! @curemeso

[Anna Nowak @perth_meso_dr]

Great to see this important trial is now open in the USA also. #DREAM3R #mesothelioma @TrialsCentre @TOGAANZ @MartinStockler

[PrECOG @PrECOGonc]

Press release: Durvalumab #immunotherapy proceeds to phase 3 trial for malignant pleural #mesothelioma. The #DREAM3R study is being led by @FordePatrick in the US and @perth_meso_dr in Australia & NZ. Learn more: https://t.co/yLjOFDsFJy #lcsm cc: @TrialsCentre @TOGAANZ

[Lecia Sequist, MD, MPH, FASCO @LeciaSequist]

Great poster from @NouraChoudhury @RielyMD confirming that, like canonical EGFR mut, Exon 20 tumors have better outcomes to chemo than wt tumors, but worse outcomes w/ IO #TTLC21 @Exon20Group #LCSM @EGFRResisters

[Matty Britland @mbritland]

@AUSmedaffairs @teegstar @MedicinesAus @ARCSAustralia Very proud to share this open upcoming @AUSmedaffairs event. Very proud to work in pharmaceutical medicine

[APPA @AUSmedaffairs]

As vaccines developed in record time are rolled out, on March 11th @teegstar will join key experts in the healthcare sector to reflect on an unprecendented year @MedicinesAus @ARCSAustralia - keep an eye out for an invite to our Symposium via your professional association